Importantly, no signs of autoimmune toxicity have been reported in Cbl-b-deficient mice challenged with tumors, neither short-term, while rejecting tumors, nor long-term, up to 1 year after tumor rejection [125,126,127,129,138]. The gene discussed is CBLB; the disease is neoplasm.